nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ALB—acquired immunodeficiency syndrome	0.176	1	CbGaD
Gefitinib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.03	0.052	CbGbCtD
Gefitinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0202	0.0351	CbGbCtD
Gefitinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0183	0.0317	CbGbCtD
Gefitinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0183	0.0317	CbGbCtD
Gefitinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0175	0.0304	CbGbCtD
Gefitinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0148	0.0257	CbGbCtD
Gefitinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0136	0.0235	CbGbCtD
Gefitinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0134	0.0232	CbGbCtD
Gefitinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0134	0.0232	CbGbCtD
Gefitinib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0127	0.022	CbGbCtD
Gefitinib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0126	0.0219	CbGbCtD
Gefitinib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0121	0.021	CbGbCtD
Gefitinib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0207	CbGbCtD
Gefitinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0115	0.02	CbGbCtD
Gefitinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0112	0.0194	CbGbCtD
Gefitinib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0187	CbGbCtD
Gefitinib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0187	CbGbCtD
Gefitinib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0105	0.0183	CbGbCtD
Gefitinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0101	0.0176	CbGbCtD
Gefitinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0101	0.0176	CbGbCtD
Gefitinib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00991	0.0172	CbGbCtD
Gefitinib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00991	0.0172	CbGbCtD
Gefitinib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00964	0.0167	CbGbCtD
Gefitinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00962	0.0167	CbGbCtD
Gefitinib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00931	0.0162	CbGbCtD
Gefitinib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00906	0.0157	CbGbCtD
Gefitinib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00906	0.0157	CbGbCtD
Gefitinib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00903	0.0157	CbGbCtD
Gefitinib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00896	0.0156	CbGbCtD
Gefitinib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00896	0.0156	CbGbCtD
Gefitinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0087	0.0151	CbGbCtD
Gefitinib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0082	0.0142	CbGbCtD
Gefitinib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0082	0.0142	CbGbCtD
Gefitinib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00817	0.0142	CbGbCtD
Gefitinib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00817	0.0142	CbGbCtD
Gefitinib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00783	0.0136	CbGbCtD
Gefitinib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00774	0.0134	CbGbCtD
Gefitinib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00751	0.013	CbGbCtD
Gefitinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00751	0.013	CbGbCtD
Gefitinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00729	0.0127	CbGbCtD
Gefitinib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00708	0.0123	CbGbCtD
Gefitinib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00687	0.0119	CbGbCtD
Gefitinib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00679	0.0118	CbGbCtD
Gefitinib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00679	0.0118	CbGbCtD
Gefitinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00659	0.0114	CbGbCtD
Gefitinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00659	0.0114	CbGbCtD
Gefitinib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00651	0.0113	CbGbCtD
Gefitinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00632	0.011	CbGbCtD
Gefitinib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00621	0.0108	CbGbCtD
Gefitinib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00621	0.0108	CbGbCtD
Gefitinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00613	0.0106	CbGbCtD
Gefitinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00576	0.01	CbGbCtD
Gefitinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00576	0.01	CbGbCtD
Gefitinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00521	0.00905	CbGbCtD
Gefitinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00521	0.00905	CbGbCtD
Gefitinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00489	0.00849	CbGbCtD
Gefitinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0045	0.00781	CbGbCtD
Gefitinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00437	0.00758	CbGbCtD
Gefitinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00395	0.00686	CbGbCtD
Gefitinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00395	0.00686	CbGbCtD
Gefitinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00379	0.00658	CbGbCtD
Gefitinib—ORM1—saliva—acquired immunodeficiency syndrome	0.00219	0.0301	CbGeAlD
Gefitinib—SBK1—retina—acquired immunodeficiency syndrome	0.00175	0.024	CbGeAlD
Gefitinib—STK10—blood plasma—acquired immunodeficiency syndrome	0.00131	0.0181	CbGeAlD
Gefitinib—SBK1—blood—acquired immunodeficiency syndrome	0.00117	0.0161	CbGeAlD
Gefitinib—SBK1—spinal cord—acquired immunodeficiency syndrome	0.00113	0.0155	CbGeAlD
Gefitinib—CHEK2—blood—acquired immunodeficiency syndrome	0.00102	0.014	CbGeAlD
Gefitinib—CHEK2—bone marrow—acquired immunodeficiency syndrome	0.000985	0.0135	CbGeAlD
Gefitinib—CSNK1E—retina—acquired immunodeficiency syndrome	0.000965	0.0133	CbGeAlD
Gefitinib—CHEK2—vagina—acquired immunodeficiency syndrome	0.000944	0.013	CbGeAlD
Gefitinib—CHEK2—lung—acquired immunodeficiency syndrome	0.000893	0.0123	CbGeAlD
Gefitinib—MKNK2—retina—acquired immunodeficiency syndrome	0.000885	0.0122	CbGeAlD
Gefitinib—MKNK1—retina—acquired immunodeficiency syndrome	0.000874	0.012	CbGeAlD
Gefitinib—CSNK1E—skin of body—acquired immunodeficiency syndrome	0.000847	0.0116	CbGeAlD
Gefitinib—ERBB3—skin of body—acquired immunodeficiency syndrome	0.000817	0.0112	CbGeAlD
Gefitinib—EPHA6—nervous system—acquired immunodeficiency syndrome	0.000741	0.0102	CbGeAlD
Gefitinib—MAP3K19—lung—acquired immunodeficiency syndrome	0.000728	0.01	CbGeAlD
Gefitinib—SBK1—brain—acquired immunodeficiency syndrome	0.000725	0.00996	CbGeAlD
Gefitinib—HIPK4—brain—acquired immunodeficiency syndrome	0.000717	0.00985	CbGeAlD
Gefitinib—EPHA6—central nervous system—acquired immunodeficiency syndrome	0.000714	0.00981	CbGeAlD
Gefitinib—SBK1—lymph node—acquired immunodeficiency syndrome	0.000701	0.00963	CbGeAlD
Gefitinib—CSNK1E—digestive system—acquired immunodeficiency syndrome	0.000678	0.00931	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—acquired immunodeficiency syndrome	0.000675	0.00928	CbGeAlD
Gefitinib—MAP3K19—nervous system—acquired immunodeficiency syndrome	0.000674	0.00926	CbGeAlD
Gefitinib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000673	0.00924	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—acquired immunodeficiency syndrome	0.000662	0.00909	CbGeAlD
Gefitinib—ERBB3—digestive system—acquired immunodeficiency syndrome	0.000654	0.00898	CbGeAlD
Gefitinib—MAP3K19—central nervous system—acquired immunodeficiency syndrome	0.000649	0.00891	CbGeAlD
Gefitinib—CSNK1E—blood—acquired immunodeficiency syndrome	0.000645	0.00887	CbGeAlD
Gefitinib—IRAK4—blood—acquired immunodeficiency syndrome	0.000635	0.00873	CbGeAlD
Gefitinib—CHEK2—brain—acquired immunodeficiency syndrome	0.000632	0.00868	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—acquired immunodeficiency syndrome	0.000629	0.00865	CbGeAlD
Gefitinib—CSNK1E—spinal cord—acquired immunodeficiency syndrome	0.000622	0.00854	CbGeAlD
Gefitinib—MKNK2—digestive system—acquired immunodeficiency syndrome	0.000622	0.00854	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—acquired immunodeficiency syndrome	0.000621	0.00854	CbGeAlD
Gefitinib—IRAK4—bone marrow—acquired immunodeficiency syndrome	0.000615	0.00845	CbGeAlD
Gefitinib—MKNK1—digestive system—acquired immunodeficiency syndrome	0.000614	0.00843	CbGeAlD
Gefitinib—IRAK4—spinal cord—acquired immunodeficiency syndrome	0.000612	0.00841	CbGeAlD
Gefitinib—CHEK2—lymph node—acquired immunodeficiency syndrome	0.00061	0.00839	CbGeAlD
Gefitinib—ERBB3—spinal cord—acquired immunodeficiency syndrome	0.0006	0.00824	CbGeAlD
Gefitinib—CSNK1E—vagina—acquired immunodeficiency syndrome	0.000598	0.00822	CbGeAlD
Gefitinib—MKNK2—blood—acquired immunodeficiency syndrome	0.000592	0.00814	CbGeAlD
Gefitinib—IRAK1—blood—acquired immunodeficiency syndrome	0.000592	0.00814	CbGeAlD
Gefitinib—IRAK4—vagina—acquired immunodeficiency syndrome	0.000589	0.00809	CbGeAlD
Gefitinib—EGFR—lung—acquired immunodeficiency syndrome	0.000588	0.00808	CbGeAlD
Gefitinib—MKNK1—blood—acquired immunodeficiency syndrome	0.000585	0.00803	CbGeAlD
Gefitinib—MKNK2—bone marrow—acquired immunodeficiency syndrome	0.000573	0.00787	CbGeAlD
Gefitinib—IRAK1—bone marrow—acquired immunodeficiency syndrome	0.000573	0.00787	CbGeAlD
Gefitinib—MKNK2—spinal cord—acquired immunodeficiency syndrome	0.000571	0.00784	CbGeAlD
Gefitinib—EPHA6—brain—acquired immunodeficiency syndrome	0.000567	0.00778	CbGeAlD
Gefitinib—CSNK1E—lung—acquired immunodeficiency syndrome	0.000566	0.00777	CbGeAlD
Gefitinib—MKNK1—bone marrow—acquired immunodeficiency syndrome	0.000566	0.00777	CbGeAlD
Gefitinib—MKNK1—spinal cord—acquired immunodeficiency syndrome	0.000563	0.00774	CbGeAlD
Gefitinib—IRAK4—lung—acquired immunodeficiency syndrome	0.000557	0.00765	CbGeAlD
Gefitinib—MKNK2—vagina—acquired immunodeficiency syndrome	0.000549	0.00754	CbGeAlD
Gefitinib—ERBB3—lung—acquired immunodeficiency syndrome	0.000546	0.0075	CbGeAlD
Gefitinib—MKNK1—vagina—acquired immunodeficiency syndrome	0.000542	0.00745	CbGeAlD
Gefitinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.00053	0.00728	CbGeAlD
Gefitinib—CSNK1E—nervous system—acquired immunodeficiency syndrome	0.000524	0.0072	CbGeAlD
Gefitinib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000522	0.00717	CbGeAlD
Gefitinib—MKNK2—lung—acquired immunodeficiency syndrome	0.000519	0.00713	CbGeAlD
Gefitinib—IRAK1—lung—acquired immunodeficiency syndrome	0.000519	0.00713	CbGeAlD
Gefitinib—IRAK4—nervous system—acquired immunodeficiency syndrome	0.000516	0.00709	CbGeAlD
Gefitinib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000515	0.00708	CbGeAlD
Gefitinib—MKNK1—lung—acquired immunodeficiency syndrome	0.000513	0.00704	CbGeAlD
Gefitinib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	0.000512	0.00703	CbGeAlD
Gefitinib—ERBB3—nervous system—acquired immunodeficiency syndrome	0.000506	0.00695	CbGeAlD
Gefitinib—STK10—digestive system—acquired immunodeficiency syndrome	0.000505	0.00694	CbGeAlD
Gefitinib—CSNK1E—central nervous system—acquired immunodeficiency syndrome	0.000504	0.00693	CbGeAlD
Gefitinib—IRAK4—central nervous system—acquired immunodeficiency syndrome	0.000497	0.00682	CbGeAlD
Gefitinib—ERBB3—central nervous system—acquired immunodeficiency syndrome	0.000487	0.00669	CbGeAlD
Gefitinib—STK10—blood—acquired immunodeficiency syndrome	0.000482	0.00662	CbGeAlD
Gefitinib—MKNK2—nervous system—acquired immunodeficiency syndrome	0.000481	0.00661	CbGeAlD
Gefitinib—MKNK1—nervous system—acquired immunodeficiency syndrome	0.000475	0.00652	CbGeAlD
Gefitinib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000466	0.0064	CbGeAlD
Gefitinib—MKNK2—central nervous system—acquired immunodeficiency syndrome	0.000463	0.00636	CbGeAlD
Gefitinib—MKNK1—central nervous system—acquired immunodeficiency syndrome	0.000457	0.00628	CbGeAlD
Gefitinib—STK10—vagina—acquired immunodeficiency syndrome	0.000446	0.00613	CbGeAlD
Gefitinib—MAP2K5—blood—acquired immunodeficiency syndrome	0.00043	0.00591	CbGeAlD
Gefitinib—STK10—lung—acquired immunodeficiency syndrome	0.000422	0.0058	CbGeAlD
Gefitinib—EGFR—brain—acquired immunodeficiency syndrome	0.000417	0.00572	CbGeAlD
Gefitinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000414	0.00569	CbGeAlD
Gefitinib—EGFR—lymph node—acquired immunodeficiency syndrome	0.000402	0.00553	CbGeAlD
Gefitinib—CSNK1E—brain—acquired immunodeficiency syndrome	0.000401	0.0055	CbGeAlD
Gefitinib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000399	0.00548	CbGeAlD
Gefitinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000398	0.00547	CbGeAlD
Gefitinib—IRAK4—brain—acquired immunodeficiency syndrome	0.000394	0.00542	CbGeAlD
Gefitinib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000391	0.00538	CbGeAlD
Gefitinib—STK10—nervous system—acquired immunodeficiency syndrome	0.000391	0.00537	CbGeAlD
Gefitinib—CSNK1E—lymph node—acquired immunodeficiency syndrome	0.000387	0.00532	CbGeAlD
Gefitinib—ERBB3—brain—acquired immunodeficiency syndrome	0.000386	0.00531	CbGeAlD
Gefitinib—IRAK4—lymph node—acquired immunodeficiency syndrome	0.000381	0.00523	CbGeAlD
Gefitinib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000377	0.00518	CbGeAlD
Gefitinib—STK10—central nervous system—acquired immunodeficiency syndrome	0.000376	0.00517	CbGeAlD
Gefitinib—ERBB3—lymph node—acquired immunodeficiency syndrome	0.000373	0.00513	CbGeAlD
Gefitinib—MKNK2—brain—acquired immunodeficiency syndrome	0.000368	0.00505	CbGeAlD
Gefitinib—IRAK1—brain—acquired immunodeficiency syndrome	0.000368	0.00505	CbGeAlD
Gefitinib—MKNK1—brain—acquired immunodeficiency syndrome	0.000363	0.00499	CbGeAlD
Gefitinib—MKNK2—lymph node—acquired immunodeficiency syndrome	0.000355	0.00488	CbGeAlD
Gefitinib—IRAK1—lymph node—acquired immunodeficiency syndrome	0.000355	0.00488	CbGeAlD
Gefitinib—MKNK1—lymph node—acquired immunodeficiency syndrome	0.000351	0.00482	CbGeAlD
Gefitinib—ORM1—blood—acquired immunodeficiency syndrome	0.000349	0.0048	CbGeAlD
Gefitinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.000349	0.0048	CbGeAlD
Gefitinib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000338	0.00464	CbGeAlD
Gefitinib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000336	0.00462	CbGeAlD
Gefitinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000336	0.00462	CbGeAlD
Gefitinib—ORM1—lung—acquired immunodeficiency syndrome	0.000306	0.00421	CbGeAlD
Gefitinib—STK10—brain—acquired immunodeficiency syndrome	0.000299	0.00411	CbGeAlD
Gefitinib—STK10—lymph node—acquired immunodeficiency syndrome	0.000289	0.00397	CbGeAlD
Gefitinib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000283	0.00389	CbGeAlD
Gefitinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000282	0.00387	CbGeAlD
Gefitinib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000273	0.00375	CbGeAlD
Gefitinib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000267	0.00367	CbGeAlD
Gefitinib—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000261	0.00358	CbGeAlD
Gefitinib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000259	0.00355	CbGeAlD
Gefitinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000258	0.00354	CbGeAlD
Gefitinib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000247	0.00339	CbGeAlD
Gefitinib—Erlotinib—ALB—acquired immunodeficiency syndrome	0.000234	0.603	CrCbGaD
Gefitinib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000229	0.00314	CbGeAlD
Gefitinib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000209	0.00288	CbGeAlD
Gefitinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000209	0.00287	CbGeAlD
Gefitinib—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000208	0.00286	CbGeAlD
Gefitinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000204	0.0028	CbGeAlD
Gefitinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000202	0.00278	CbGeAlD
Gefitinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000202	0.00277	CbGeAlD
Gefitinib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000201	0.00276	CbGeAlD
Gefitinib—CYP1A1—blood—acquired immunodeficiency syndrome	0.000199	0.00273	CbGeAlD
Gefitinib—CYP3A5—blood—acquired immunodeficiency syndrome	0.000194	0.00267	CbGeAlD
Gefitinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000194	0.00266	CbGeAlD
Gefitinib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000191	0.00263	CbGeAlD
Gefitinib—ALB—brain—acquired immunodeficiency syndrome	0.00019	0.00261	CbGeAlD
Gefitinib—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000184	0.00253	CbGeAlD
Gefitinib—ALB—lymph node—acquired immunodeficiency syndrome	0.000184	0.00252	CbGeAlD
Gefitinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000183	0.00252	CbGeAlD
Gefitinib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.00018	0.00247	CbGeAlD
Gefitinib—CYP1A1—lung—acquired immunodeficiency syndrome	0.000174	0.00239	CbGeAlD
Gefitinib—CYP3A5—lung—acquired immunodeficiency syndrome	0.00017	0.00234	CbGeAlD
Gefitinib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000169	0.00108	CcSEcCtD
Gefitinib—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.00108	CcSEcCtD
Gefitinib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00108	CcSEcCtD
Gefitinib—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000168	0.00107	CcSEcCtD
Gefitinib—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000168	0.00107	CcSEcCtD
Gefitinib—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000167	0.00107	CcSEcCtD
Gefitinib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000167	0.00107	CcSEcCtD
Gefitinib—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000167	0.00107	CcSEcCtD
Gefitinib—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000167	0.00107	CcSEcCtD
Gefitinib—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000167	0.00107	CcSEcCtD
Gefitinib—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000167	0.00106	CcSEcCtD
Gefitinib—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000166	0.00106	CcSEcCtD
Gefitinib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.00105	CcSEcCtD
Gefitinib—Malaise—Delavirdine—acquired immunodeficiency syndrome	0.000165	0.00105	CcSEcCtD
Gefitinib—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000165	0.00105	CcSEcCtD
Gefitinib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000164	0.00105	CcSEcCtD
Gefitinib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.00104	CcSEcCtD
Gefitinib—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000163	0.00104	CcSEcCtD
Gefitinib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000163	0.00104	CcSEcCtD
Gefitinib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000163	0.00104	CcSEcCtD
Gefitinib—Shock—Indinavir—acquired immunodeficiency syndrome	0.000162	0.00104	CcSEcCtD
Gefitinib—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000162	0.00104	CcSEcCtD
Gefitinib—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000162	0.00103	CcSEcCtD
Gefitinib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000162	0.00103	CcSEcCtD
Gefitinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000162	0.00103	CcSEcCtD
Gefitinib—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000162	0.00103	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000162	0.00103	CcSEcCtD
Gefitinib—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000161	0.00103	CcSEcCtD
Gefitinib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000161	0.00103	CcSEcCtD
Gefitinib—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000161	0.00222	CbGeAlD
Gefitinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000161	0.00103	CcSEcCtD
Gefitinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.00103	CcSEcCtD
Gefitinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00016	0.00102	CcSEcCtD
Gefitinib—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.00016	0.00102	CcSEcCtD
Gefitinib—Cough—Delavirdine—acquired immunodeficiency syndrome	0.00016	0.00102	CcSEcCtD
Gefitinib—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000159	0.00102	CcSEcCtD
Gefitinib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000159	0.00102	CcSEcCtD
Gefitinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000159	0.00102	CcSEcCtD
Gefitinib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000158	0.00101	CcSEcCtD
Gefitinib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.00101	CcSEcCtD
Gefitinib—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000157	0.001	CcSEcCtD
Gefitinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.000998	CcSEcCtD
Gefitinib—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000156	0.000995	CcSEcCtD
Gefitinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.000991	CcSEcCtD
Gefitinib—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000155	0.00213	CbGeAlD
Gefitinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000154	0.000985	CcSEcCtD
Gefitinib—Vandetanib—ALB—acquired immunodeficiency syndrome	0.000154	0.397	CrCbGaD
Gefitinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000154	0.00212	CbGeAlD
Gefitinib—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000979	CcSEcCtD
Gefitinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000153	0.000978	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.000978	CcSEcCtD
Gefitinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.000977	CcSEcCtD
Gefitinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000153	0.0021	CbGeAlD
Gefitinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000976	CcSEcCtD
Gefitinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000975	CcSEcCtD
Gefitinib—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000973	CcSEcCtD
Gefitinib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000152	0.000972	CcSEcCtD
Gefitinib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.000969	CcSEcCtD
Gefitinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.000969	CcSEcCtD
Gefitinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000152	0.000969	CcSEcCtD
Gefitinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.000967	CcSEcCtD
Gefitinib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000151	0.000963	CcSEcCtD
Gefitinib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000151	0.00207	CbGeAlD
Gefitinib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00015	0.00096	CcSEcCtD
Gefitinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.00096	CcSEcCtD
Gefitinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00015	0.000955	CcSEcCtD
Gefitinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00015	0.000955	CcSEcCtD
Gefitinib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000149	0.000949	CcSEcCtD
Gefitinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000148	0.000947	CcSEcCtD
Gefitinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000148	0.000946	CcSEcCtD
Gefitinib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000148	0.000946	CcSEcCtD
Gefitinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000148	0.000946	CcSEcCtD
Gefitinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000942	CcSEcCtD
Gefitinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000147	0.000939	CcSEcCtD
Gefitinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000147	0.000938	CcSEcCtD
Gefitinib—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000937	CcSEcCtD
Gefitinib—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000937	CcSEcCtD
Gefitinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000147	0.000935	CcSEcCtD
Gefitinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.000933	CcSEcCtD
Gefitinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000146	0.002	CbGeAlD
Gefitinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000145	0.000926	CcSEcCtD
Gefitinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000145	0.000925	CcSEcCtD
Gefitinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000145	0.000925	CcSEcCtD
Gefitinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000145	0.000924	CcSEcCtD
Gefitinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000144	0.000922	CcSEcCtD
Gefitinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000144	0.000921	CcSEcCtD
Gefitinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000143	0.000916	CcSEcCtD
Gefitinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.000916	CcSEcCtD
Gefitinib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000143	0.00197	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.000913	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000143	0.00091	CcSEcCtD
Gefitinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000142	0.000909	CcSEcCtD
Gefitinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000142	0.000908	CcSEcCtD
Gefitinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000908	CcSEcCtD
Gefitinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000906	CcSEcCtD
Gefitinib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000142	0.000906	CcSEcCtD
Gefitinib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000901	CcSEcCtD
Gefitinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000901	CcSEcCtD
Gefitinib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000141	0.0009	CcSEcCtD
Gefitinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000899	CcSEcCtD
Gefitinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.000896	CcSEcCtD
Gefitinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.000896	CcSEcCtD
Gefitinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00014	0.000895	CcSEcCtD
Gefitinib—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000894	CcSEcCtD
Gefitinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00014	0.000892	CcSEcCtD
Gefitinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00014	0.000892	CcSEcCtD
Gefitinib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000139	0.00089	CcSEcCtD
Gefitinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000139	0.000888	CcSEcCtD
Gefitinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000138	0.000879	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.000878	CcSEcCtD
Gefitinib—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000867	CcSEcCtD
Gefitinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000865	CcSEcCtD
Gefitinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000865	CcSEcCtD
Gefitinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000865	CcSEcCtD
Gefitinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000864	CcSEcCtD
Gefitinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000862	CcSEcCtD
Gefitinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000135	0.000862	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000859	CcSEcCtD
Gefitinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000134	0.000858	CcSEcCtD
Gefitinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.000858	CcSEcCtD
Gefitinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000856	CcSEcCtD
Gefitinib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000851	CcSEcCtD
Gefitinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000851	CcSEcCtD
Gefitinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000133	0.000851	CcSEcCtD
Gefitinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000133	0.00085	CcSEcCtD
Gefitinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000133	0.000849	CcSEcCtD
Gefitinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000842	CcSEcCtD
Gefitinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000132	0.00084	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000838	CcSEcCtD
Gefitinib—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000131	0.000837	CcSEcCtD
Gefitinib—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000834	CcSEcCtD
Gefitinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00013	0.000833	CcSEcCtD
Gefitinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00013	0.000833	CcSEcCtD
Gefitinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000831	CcSEcCtD
Gefitinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00013	0.000831	CcSEcCtD
Gefitinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.00083	CcSEcCtD
Gefitinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00013	0.000829	CcSEcCtD
Gefitinib—ABCG2—brain—acquired immunodeficiency syndrome	0.00013	0.00178	CbGeAlD
Gefitinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000828	CcSEcCtD
Gefitinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000825	CcSEcCtD
Gefitinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000129	0.000824	CcSEcCtD
Gefitinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000129	0.000824	CcSEcCtD
Gefitinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000823	CcSEcCtD
Gefitinib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000823	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000822	CcSEcCtD
Gefitinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000129	0.000822	CcSEcCtD
Gefitinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000821	CcSEcCtD
Gefitinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000129	0.000821	CcSEcCtD
Gefitinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000128	0.000816	CcSEcCtD
Gefitinib—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000815	CcSEcCtD
Gefitinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000815	CcSEcCtD
Gefitinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000128	0.000814	CcSEcCtD
Gefitinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000127	0.000813	CcSEcCtD
Gefitinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000127	0.00081	CcSEcCtD
Gefitinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000127	0.000809	CcSEcCtD
Gefitinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.000808	CcSEcCtD
Gefitinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000804	CcSEcCtD
Gefitinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000126	0.000802	CcSEcCtD
Gefitinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000126	0.000802	CcSEcCtD
Gefitinib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000125	0.00172	CbGeAlD
Gefitinib—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000796	CcSEcCtD
Gefitinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000793	CcSEcCtD
Gefitinib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.000792	CcSEcCtD
Gefitinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000792	CcSEcCtD
Gefitinib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000124	0.000791	CcSEcCtD
Gefitinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000787	CcSEcCtD
Gefitinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000787	CcSEcCtD
Gefitinib—CYP1A1—brain—acquired immunodeficiency syndrome	0.000123	0.00169	CbGeAlD
Gefitinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000786	CcSEcCtD
Gefitinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000123	0.000785	CcSEcCtD
Gefitinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000122	0.000779	CcSEcCtD
Gefitinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000122	0.000777	CcSEcCtD
Gefitinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000122	0.000776	CcSEcCtD
Gefitinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000775	CcSEcCtD
Gefitinib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000121	0.000774	CcSEcCtD
Gefitinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000771	CcSEcCtD
Gefitinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000766	CcSEcCtD
Gefitinib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000119	0.000763	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.00076	CcSEcCtD
Gefitinib—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000119	0.00164	CbGeAlD
Gefitinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000759	CcSEcCtD
Gefitinib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.000757	CcSEcCtD
Gefitinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000756	CcSEcCtD
Gefitinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.000756	CcSEcCtD
Gefitinib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000756	CcSEcCtD
Gefitinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000118	0.00163	CbGeAlD
Gefitinib—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000753	CcSEcCtD
Gefitinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000753	CcSEcCtD
Gefitinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000753	CcSEcCtD
Gefitinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000753	CcSEcCtD
Gefitinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000745	CcSEcCtD
Gefitinib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000116	0.0016	CbGeAlD
Gefitinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000737	CcSEcCtD
Gefitinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000733	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000732	CcSEcCtD
Gefitinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000731	CcSEcCtD
Gefitinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000114	0.00156	CbGeAlD
Gefitinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000725	CcSEcCtD
Gefitinib—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000725	CcSEcCtD
Gefitinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000721	CcSEcCtD
Gefitinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000721	CcSEcCtD
Gefitinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.00072	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.00072	CcSEcCtD
Gefitinib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000112	0.00154	CbGeAlD
Gefitinib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000714	CcSEcCtD
Gefitinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000714	CcSEcCtD
Gefitinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000714	CcSEcCtD
Gefitinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000704	CcSEcCtD
Gefitinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000703	CcSEcCtD
Gefitinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000702	CcSEcCtD
Gefitinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.00011	0.00151	CbGeAlD
Gefitinib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.0007	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000698	CcSEcCtD
Gefitinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000697	CcSEcCtD
Gefitinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000696	CcSEcCtD
Gefitinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000696	CcSEcCtD
Gefitinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000693	CcSEcCtD
Gefitinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000692	CcSEcCtD
Gefitinib—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000692	CcSEcCtD
Gefitinib—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000108	0.00149	CbGeAlD
Gefitinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000683	CcSEcCtD
Gefitinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000681	CcSEcCtD
Gefitinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000674	CcSEcCtD
Gefitinib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000674	CcSEcCtD
Gefitinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000105	0.000673	CcSEcCtD
Gefitinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.00067	CcSEcCtD
Gefitinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.00067	CcSEcCtD
Gefitinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000105	0.00067	CcSEcCtD
Gefitinib—Rash—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000664	CcSEcCtD
Gefitinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000664	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000661	CcSEcCtD
Gefitinib—ABCB1—blood—acquired immunodeficiency syndrome	0.000103	0.00142	CbGeAlD
Gefitinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000652	CcSEcCtD
Gefitinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000649	CcSEcCtD
Gefitinib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000643	CcSEcCtD
Gefitinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000639	CcSEcCtD
Gefitinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000639	CcSEcCtD
Gefitinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	9.98e-05	0.00137	CbGeAlD
Gefitinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	9.94e-05	0.00137	CbGeAlD
Gefitinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	9.92e-05	0.000633	CcSEcCtD
Gefitinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	9.9e-05	0.000632	CcSEcCtD
Gefitinib—Rash—Efavirenz—acquired immunodeficiency syndrome	9.83e-05	0.000628	CcSEcCtD
Gefitinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	9.82e-05	0.000627	CcSEcCtD
Gefitinib—Nausea—Indinavir—acquired immunodeficiency syndrome	9.8e-05	0.000626	CcSEcCtD
Gefitinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	9.79e-05	0.000625	CcSEcCtD
Gefitinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	9.76e-05	0.000623	CcSEcCtD
Gefitinib—ABCB1—vagina—acquired immunodeficiency syndrome	9.56e-05	0.00131	CbGeAlD
Gefitinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	9.53e-05	0.000608	CcSEcCtD
Gefitinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	9.49e-05	0.000606	CcSEcCtD
Gefitinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	9.44e-05	0.000603	CcSEcCtD
Gefitinib—Rash—Delavirdine—acquired immunodeficiency syndrome	9.41e-05	0.000601	CcSEcCtD
Gefitinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	9.4e-05	0.0006	CcSEcCtD
Gefitinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	9.4e-05	0.0006	CcSEcCtD
Gefitinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	9.33e-05	0.000596	CcSEcCtD
Gefitinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	9.26e-05	0.000591	CcSEcCtD
Gefitinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	9.09e-05	0.00058	CcSEcCtD
Gefitinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	9.09e-05	0.00058	CcSEcCtD
Gefitinib—ABCB1—lung—acquired immunodeficiency syndrome	9.04e-05	0.00124	CbGeAlD
Gefitinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	8.96e-05	0.000572	CcSEcCtD
Gefitinib—CYP2D6—brain—acquired immunodeficiency syndrome	8.9e-05	0.00122	CbGeAlD
Gefitinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	8.86e-05	0.000566	CcSEcCtD
Gefitinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	8.77e-05	0.00056	CcSEcCtD
Gefitinib—Rash—Ritonavir—acquired immunodeficiency syndrome	8.7e-05	0.000555	CcSEcCtD
Gefitinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	8.69e-05	0.000555	CcSEcCtD
Gefitinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	8.67e-05	0.000553	CcSEcCtD
Gefitinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	8.44e-05	0.000539	CcSEcCtD
Gefitinib—ABCB1—nervous system—acquired immunodeficiency syndrome	8.37e-05	0.00115	CbGeAlD
Gefitinib—Rash—Saquinavir—acquired immunodeficiency syndrome	8.37e-05	0.000535	CcSEcCtD
Gefitinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	8.37e-05	0.000534	CcSEcCtD
Gefitinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	8.2e-05	0.000523	CcSEcCtD
Gefitinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	8.06e-05	0.00111	CbGeAlD
Gefitinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	8.06e-05	0.000514	CcSEcCtD
Gefitinib—Rash—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.00051	CcSEcCtD
Gefitinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	7.98e-05	0.000509	CcSEcCtD
Gefitinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	7.89e-05	0.000504	CcSEcCtD
Gefitinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	7.53e-05	0.00048	CcSEcCtD
Gefitinib—ABCB1—brain—acquired immunodeficiency syndrome	6.4e-05	0.000879	CbGeAlD
Gefitinib—ABCB1—lymph node—acquired immunodeficiency syndrome	6.19e-05	0.00085	CbGeAlD
Gefitinib—ERBB3—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.8e-05	0.00152	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD79A—acquired immunodeficiency syndrome	2.77e-05	0.0015	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	2.76e-05	0.0015	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.75e-05	0.0015	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.75e-05	0.00149	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.74e-05	0.00149	CbGpPWpGaD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	2.74e-05	0.00149	CbGpPWpGaD
Gefitinib—EGFR—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.73e-05	0.00148	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	2.7e-05	0.00146	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.68e-05	0.00146	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MBL2—acquired immunodeficiency syndrome	2.68e-05	0.00145	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	2.67e-05	0.00145	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.64e-05	0.00143	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.63e-05	0.00143	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.62e-05	0.00142	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.62e-05	0.00142	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.62e-05	0.00142	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.61e-05	0.00142	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.59e-05	0.00141	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.59e-05	0.00141	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.59e-05	0.00141	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.58e-05	0.0014	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.00138	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CCR2—acquired immunodeficiency syndrome	2.52e-05	0.00137	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.5e-05	0.00136	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.49e-05	0.00135	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	2.47e-05	0.00134	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.44e-05	0.00133	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.44e-05	0.00133	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.44e-05	0.00133	CbGpPWpGaD
Gefitinib—ERBB3—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.44e-05	0.00133	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	2.44e-05	0.00132	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.43e-05	0.00132	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.43e-05	0.00132	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.42e-05	0.00131	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	2.41e-05	0.00131	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.4e-05	0.0013	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	2.4e-05	0.0013	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.39e-05	0.0013	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.37e-05	0.00129	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—IL6—acquired immunodeficiency syndrome	2.34e-05	0.00127	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.33e-05	0.00126	CbGpPWpGaD
Gefitinib—EGFR—Disease—CCNT1—acquired immunodeficiency syndrome	2.32e-05	0.00126	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNA1—acquired immunodeficiency syndrome	2.27e-05	0.00123	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.27e-05	0.00123	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD40LG—acquired immunodeficiency syndrome	2.26e-05	0.00122	CbGpPWpGaD
Gefitinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.24e-05	0.00122	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CSF2—acquired immunodeficiency syndrome	2.23e-05	0.00121	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD8A—acquired immunodeficiency syndrome	2.23e-05	0.00121	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.22e-05	0.00121	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD79A—acquired immunodeficiency syndrome	2.21e-05	0.0012	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.2e-05	0.00119	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.2e-05	0.00119	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CXCR4—acquired immunodeficiency syndrome	2.19e-05	0.00119	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ACTG1—acquired immunodeficiency syndrome	2.18e-05	0.00118	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	2.17e-05	0.00118	CbGpPWpGaD
Gefitinib—ERBB3—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.16e-05	0.00117	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-B—acquired immunodeficiency syndrome	2.15e-05	0.00116	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.14e-05	0.00116	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.14e-05	0.00116	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.12e-05	0.00115	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.12e-05	0.00115	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.11e-05	0.00115	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CCR2—acquired immunodeficiency syndrome	2.1e-05	0.00114	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.07e-05	0.00112	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	2.02e-05	0.0011	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.01e-05	0.00109	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.01e-05	0.00109	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CCR5—acquired immunodeficiency syndrome	1.97e-05	0.00107	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.97e-05	0.00107	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.94e-05	0.00105	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.91e-05	0.00104	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNA1—acquired immunodeficiency syndrome	1.89e-05	0.00103	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	1.88e-05	0.00102	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.87e-05	0.00102	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD79A—acquired immunodeficiency syndrome	1.84e-05	0.000997	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	1.81e-05	0.000981	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.8e-05	0.00098	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40LG—acquired immunodeficiency syndrome	1.8e-05	0.000976	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MBL2—acquired immunodeficiency syndrome	1.79e-05	0.000973	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD8A—acquired immunodeficiency syndrome	1.78e-05	0.000965	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000965	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.77e-05	0.000963	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.76e-05	0.000953	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.75e-05	0.000952	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.72e-05	0.000936	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.72e-05	0.000936	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-B—acquired immunodeficiency syndrome	1.71e-05	0.000929	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.7e-05	0.000923	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.7e-05	0.000921	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.69e-05	0.000919	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.68e-05	0.000914	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.67e-05	0.000907	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000903	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	1.65e-05	0.000896	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.65e-05	0.000895	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.63e-05	0.000888	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	1.63e-05	0.000886	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.000886	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	1.63e-05	0.000885	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.63e-05	0.000883	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.63e-05	0.000883	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.63e-05	0.000883	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.62e-05	0.00088	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.59e-05	0.000864	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.59e-05	0.000864	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD4—acquired immunodeficiency syndrome	1.59e-05	0.000864	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.58e-05	0.00086	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	1.57e-05	0.000852	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	1.56e-05	0.000847	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.54e-05	0.000835	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.54e-05	0.000834	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	1.53e-05	0.000833	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.000833	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.000833	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.53e-05	0.000832	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.51e-05	0.000819	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.5e-05	0.000816	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CCR5—acquired immunodeficiency syndrome	1.5e-05	0.000815	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.5e-05	0.000813	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000804	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—acquired immunodeficiency syndrome	1.48e-05	0.000804	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.48e-05	0.000803	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.47e-05	0.000798	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.47e-05	0.000796	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.46e-05	0.000793	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000792	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000788	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.45e-05	0.000785	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.45e-05	0.000785	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.44e-05	0.000784	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.44e-05	0.000784	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.42e-05	0.000773	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.41e-05	0.000764	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CCR2—acquired immunodeficiency syndrome	1.4e-05	0.000763	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.4e-05	0.000761	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.39e-05	0.000755	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.38e-05	0.000752	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.38e-05	0.000749	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.37e-05	0.000743	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.36e-05	0.000739	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000738	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000738	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000738	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.36e-05	0.000738	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.35e-05	0.000732	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000731	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000725	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000721	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IFNG—acquired immunodeficiency syndrome	1.33e-05	0.00072	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—acquired immunodeficiency syndrome	1.28e-05	0.000695	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.28e-05	0.000693	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.28e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNA1—acquired immunodeficiency syndrome	1.26e-05	0.000687	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.26e-05	0.000683	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—acquired immunodeficiency syndrome	1.24e-05	0.000672	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD79A—acquired immunodeficiency syndrome	1.23e-05	0.000667	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.23e-05	0.000667	CbGpPWpGaD
Gefitinib—EGFR—Disease—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.000662	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.000657	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.2e-05	0.000653	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.000648	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000646	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL2—acquired immunodeficiency syndrome	1.18e-05	0.00064	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.000634	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000631	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.16e-05	0.000628	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.000624	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.15e-05	0.000623	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000605	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.1e-05	0.000597	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.000592	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.09e-05	0.00059	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.08e-05	0.000588	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNG—acquired immunodeficiency syndrome	1.06e-05	0.000574	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.000571	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.03e-05	0.000557	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—acquired immunodeficiency syndrome	1.02e-05	0.000554	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1e-05	0.000545	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—acquired immunodeficiency syndrome	1e-05	0.000544	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.94e-06	0.00054	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.91e-06	0.000538	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CSF2—acquired immunodeficiency syndrome	9.9e-06	0.000537	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—acquired immunodeficiency syndrome	9.9e-06	0.000537	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.76e-06	0.00053	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.72e-06	0.000528	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.57e-06	0.00052	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	9.52e-06	0.000517	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—acquired immunodeficiency syndrome	9.48e-06	0.000515	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—acquired immunodeficiency syndrome	9.43e-06	0.000512	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2—acquired immunodeficiency syndrome	9.4e-06	0.00051	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.37e-06	0.000509	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.26e-06	0.000503	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.08e-06	0.000493	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.89e-06	0.000483	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	8.8e-06	0.000478	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.75e-06	0.000475	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—acquired immunodeficiency syndrome	8.61e-06	0.000467	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.54e-06	0.000464	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.54e-06	0.000464	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	8.5e-06	0.000462	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	8.38e-06	0.000455	CbGpPWpGaD
Gefitinib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	8.36e-06	0.000454	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	8e-06	0.000434	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.97e-06	0.000433	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.89e-06	0.000429	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	7.82e-06	0.000425	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.56e-06	0.000411	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.41e-06	0.000402	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.08e-06	0.000384	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—acquired immunodeficiency syndrome	6.93e-06	0.000376	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—acquired immunodeficiency syndrome	6.69e-06	0.000363	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.5e-06	0.000353	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.4e-06	0.000347	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.3e-06	0.000342	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.07e-06	0.00033	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.03e-06	0.000327	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.98e-06	0.000325	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	5.89e-06	0.00032	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.85e-06	0.000318	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.79e-06	0.000314	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	5.75e-06	0.000312	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.72e-06	0.000311	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	5.69e-06	0.000309	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—acquired immunodeficiency syndrome	5.52e-06	0.0003	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.38e-06	0.000292	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.28e-06	0.000287	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.28e-06	0.000287	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	5.25e-06	0.000285	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	5.23e-06	0.000284	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—acquired immunodeficiency syndrome	5.1e-06	0.000277	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.06e-06	0.000275	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.69e-06	0.000254	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	4.66e-06	0.000253	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	4.6e-06	0.00025	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.7e-06	0.000201	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.57e-06	0.000194	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.38e-06	0.000184	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.37e-06	0.000183	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.34e-06	0.000181	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.15e-06	0.000171	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	3.07e-06	0.000167	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.97e-06	0.000161	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	2.84e-06	0.000154	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.58e-06	0.00014	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.52e-06	0.000137	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.37e-06	0.000129	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.35e-06	0.000128	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.99e-06	0.000108	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.55e-06	8.42e-05	CbGpPWpGaD
